Cellebrite DI Ltd [CLBT] stock prices are down -1.06% to $17.75 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLBT shares have lost -7.79% over the last week, with a monthly amount glided 5.78%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cellebrite DI Ltd [NASDAQ: CLBT] stock has seen the most recent analyst activity on March 28, 2024, when Needham reiterated its Buy rating and also boosted its price target to $13.50 from $13. Previously, William Blair upgraded its rating to Outperform on March 13, 2024. On February 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $12 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $11 on July 19, 2023. William Blair downgraded its rating to a Mkt Perform. BofA Securities downgraded its rating to Neutral for this stock on August 12, 2022, and downed its price target to $6. In a note dated February 24, 2022, JP Morgan initiated an Overweight rating and provided a target price of $10.50 on this stock.
The stock price of Cellebrite DI Ltd [CLBT] has been fluctuating between $10.24 and $26.30 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Cellebrite DI Ltd [NASDAQ: CLBT] shares were valued at $17.75 at the most recent close of the market. An investor can expect a potential return of 12.68% based on the average CLBT price forecast.
Analyzing the CLBT fundamentals
The Cellebrite DI Ltd [NASDAQ:CLBT] reported sales of 401.20M for trailing twelve months, representing a surge of 17.24%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at -0.69%, and Net Profit Margin reading is -0.71%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -1.99 and Total Capital is 0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.17 points at the first support level, and at 16.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.64, and for the 2nd resistance point, it is at 19.52.
Ratios To Look Out For
It’s worth pointing out that Cellebrite DI Ltd [NASDAQ:CLBT]’s Current Ratio is 1.90. Further, the Quick Ratio stands at 1.87, while the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 10.59, the price to book ratio is 12.39.
Transactions by insiders
Recent insider trading involved LEEOR MOSHE BEN-PERETZ, Officer, that happened on Mar 25 ’25 when 18512.0 shares were purchased. Officer, LEEOR MOSHE BEN-PERETZ completed a deal on Mar 19 ’25 to buy 15680.0 shares. Meanwhile, Officer YOSEF CARMIL bought 0.2 million shares on Mar 17 ’25.
